HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Raises Price Target to $32

Benzinga · 2d ago
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $30 to $32.